RecruitingNCT01276470
Environmental Risk Factors for the Anti-synthetase Syndrome
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- Principal Investigator
- Adam I Schiffenbauer, M.D., AuD, CCC-A, PASCNational Institute of Environmental Health Sciences (NIEHS)
- Enrollment
- 580 enrolled
- Eligibility
- 2-100 years · All sexes
- Timeline
- 2011
Study locations (8)
- University of Miami Hospital, Miami, Florida, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Mid-Atlantic Kaiser Permanente, Rockville, Maryland, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Rochester, Minnesota, United States
- NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01276470 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH